Related Experiment Video

Updated: Oct 27, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K

Metastatic colorectal cancer: Perspectives on long non-coding RNAs and promising therapeutics

Chunyuan Tang1, Junqing Liu2, Qingqing Hu3

  • 1Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, China.

European Journal of Pharmacology
|July 25, 2021
PubMed

Insights

Long non-coding RNAs (lncRNAs) are revolutionizing metastatic colorectal cancer (mCRC) research. Understanding lncRNA functions offers new hope for developing innovative diagnostic and therapeutic strategies against mCRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastatic colorectal cancer (mCRC) remains a significant challenge with limited therapeutic options.
  • Long non-coding RNAs (lncRNAs) have emerged as critical regulators in various biological processes, including cancer.
  • lncRNAs are increasingly recognized for their roles in the pathophysiology of mCRC.

Purpose of the Study:

  • To review the current understanding of lncRNA mechanisms.
  • To summarize the regulatory roles of lncRNAs in mCRC.
  • To discuss the potential of lncRNA-based therapeutics for mCRC.

Main Methods:

  • Literature review of studies on lncRNAs in mCRC.
  • Analysis of lncRNA modes of action and regulatory functions.
  • Evaluation of lncRNA-based therapeutic strategies.

Main Results:

  • lncRNAs significantly influence the development and progression of mCRC.
  • Specific lncRNAs exhibit distinct regulatory roles in mCRC.
  • lncRNA research provides novel insights into mCRC pathogenesis.

Conclusions:

  • lncRNAs represent promising targets for future mCRC diagnostics.
  • lncRNA-based therapies hold potential for improved mCRC treatment outcomes.
  • Further research into lncRNAs is crucial for advancing mCRC management.
Keywords:
Colorectal cancerMechanismMetastasislncRNAs

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

788
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.7K